MA48863A - Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées - Google Patents

Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Info

Publication number
MA48863A
MA48863A MA048863A MA48863A MA48863A MA 48863 A MA48863 A MA 48863A MA 048863 A MA048863 A MA 048863A MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A
Authority
MA
Morocco
Prior art keywords
tgf
fusion proteins
receptor fusion
beta type
related uses
Prior art date
Application number
MA048863A
Other languages
English (en)
Other versions
MA48863B1 (fr
Inventor
Ravindra Kumar
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority claimed from PCT/US2018/030816 external-priority patent/WO2018204594A1/fr
Publication of MA48863A publication Critical patent/MA48863A/fr
Publication of MA48863B1 publication Critical patent/MA48863B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA48863A 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées MA48863B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501229P 2017-05-04 2017-05-04
PCT/US2018/030816 WO2018204594A1 (fr) 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Publications (2)

Publication Number Publication Date
MA48863A true MA48863A (fr) 2020-04-01
MA48863B1 MA48863B1 (fr) 2023-08-31

Family

ID=88016828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48863A MA48863B1 (fr) 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Country Status (1)

Country Link
MA (1) MA48863B1 (fr)

Also Published As

Publication number Publication date
MA48863B1 (fr) 2023-08-31

Similar Documents

Publication Publication Date Title
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
DK3628049T3 (da) Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
MA44986A (fr) Protéines de fusion gdf15 et leurs utilisations
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA51291A (fr) Protéines de fusion il-2 fc modifiées
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MA46534A (fr) Protéines de fusion fc hétérodimères il15/il15r
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
DK3292141T3 (da) Fusionsproteiner
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3365364T3 (da) Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf
BR112017024757A2 (pt) composições e métodos para reprogramação de tcr utilizando proteínas de fusão
BR112018004981A2 (pt) anticorpos anti-pró-miostatina/miostatina latente e usos destes.
BR112017021040A2 (pt) anticorpos dirigidos contra proteína mucina e imunoglobulina de célula t3 (tim-3)
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3606961T3 (da) Garp-tgf-beta-antistoffer
CL2016001921A1 (es) Proteínas inmovilizadas y uso de las mismas
IL297395B1 (en) btla fusion protein agonists and uses thereof
MA49414A (fr) Protéines de fusion de dmdv et e2 et leurs utilisations